FE 999322
Alternative Names: FE-999322Latest Information Update: 17 Apr 2024
Price :
$50 *
At a glance
- Originator Ferring Pharmaceuticals
- Class Anti-inflammatories; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ulcerative colitis
Most Recent Events
- 12 Mar 2024 Phase-I clinical trials in Ulcerative colitis in USA (PO) (NCT06260267)
- 21 Feb 2024 Preclinical trials in Ulcerative colitis in Switzerland (PO,Suspension) Prior to March 2024.
- 15 Feb 2024 Ferring Pharmaceuticals plans a phase Ib trial for Ulcerative colitis in March 2024 (PO,Suspension) (NCT06260267)